A 62-year-old man with longstanding type 2 diabetes and eGFR 25 mL/min/1.73 m² is being considered for SGLT2 inhibitor therapy. According to Diabetes ...

Question

A 62-year-old man with longstanding type 2 diabetes and eGFR 25 mL/min/1.73 m² is being considered for SGLT2 inhibitor therapy. According to Diabetes Canada and cardiorenal guidelines, what is the primary rationale for starting an SGLT2 inhibitor in this context?

Accepted Answer

To reduce risk of heart failure hospitalisation and slow CKD progression

Answer

To achieve large additional HbA1c reduction

Answer

To promote significant weight gain

Answer

To replace ACE inhibitor therapy

Answer

To correct anaemia

ca-mccqe1 MCQ (SBA): SGLT2 inhibitor use in CKD and diabetes

A 62-year-old man with longstanding type 2 diabetes and eGFR 25 mL/min/1.73 m² is being considered for SGLT2 inhibitor therapy. According to Diabetes Canada and cardiorenal guidelines, what is the primary rationale for starting an SGLT2 inhibitor in this context?